FluGen Inc. Company Profile

20:04 EDT 21st October 2018 | BioPortfolio

FluGen, Inc. is a clinical stage vaccine company focused on improving the breadth and effectiveness of influenza vaccines. The Company’s technology comes from the laboratory of Dr. Yoshihiro Kawaoka at the University of Wisconsin, Madison. It’s lead product candidate, RedeeFlu™ is a universal flu vaccine which is based on the knowledge that a natural or “wild-type” flu infection prevents people from being infected in subsequent years. RedeeFlu™ has demonstrated a robust immunology profile that works on multiple effector systems and appears to trick the body into believing it has been infected while not displaying flu symptoms. RedeeFlu™ will enter Phase 2 clinical trials in 2018.

News Articles [9 Associated News Articles listed on BioPortfolio]

FluGen doses first subject in new study of M2SR for influenza

FluGen has dosed the first subject in a new clinical trial evaluating the M2SR vaccine to treat subjects with an...Read More... The post FluGen doses first subject in new study of M2SR for influenza a...

NIH Using Vaccines from Madison Startup FluGen in New Clinical Trial

Researchers are testing a flu vaccine developed by FluGen, a Madison, WI-based startup, to determine whether it can protect recipients against strains of the virus that vary from the predominant strai...

FluGen to Study Versatility of Its Universal Flu Vaccine Candidate

The U.S. is coming off the worst influenza season in nearly a decade, highlighting the potential benefit of a universal flu vaccine that could protect against multiple strains of the disease. One comp...

FluGen Completes Dosing of Phase 2 Study to Assess Effectiveness of Novel Influenza Vaccine Designed to Protect Against Mismatched Strains

—Influenza challenge virus genetically drifted by six years from vaccine strain— FluGen, Inc. announced today that all subjects have completed dosing in a first-of-...

FluGen Begins Enrollment of Clinical Trial of Novel Investigational Influenza Vaccine Against Multi-Season Mismatched Strains

—Investigational vaccine designed to generate broad and durable immune protection over multiple influenza seasons— —Subjects challenged with influenza virus genetic...

FluGen Presents First-in-Human Phase 1a Safety and Immunogenicity Data with Novel M2SR Influenza Vaccine at ID Week

—Vaccine safe and well tolerated at all dose levels in trial— —Significant humoral, mucosal and T-cell responses produced by vaccine— —Goal of d...

FluGen May Seek Funding from $12M Gates-Backed Flu Vaccine Challenge

Last week, the Bill and Melinda Gates Foundation announced that it plans to provide researchers with up to $12 million in funding as part of a new initiative to support the development of a universal ...

FluGen Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17042018] Prices from USD $250

SummaryFluGen Inc FluGen is a developer of influenza vaccines and therapies. The company discovers, develops and commercializes new methods for the prevention and treatment of influenza infections. It...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Safety and Immunogenicity Study of an Influenza Vaccination Strategy Including an H3N2 M2SR Prime Followed by a Seasonal Quadrivalent Inactivated Vaccine Boost in a Pediatric Population 9-17 Years Old

This is a Phase I double-blind, randomized, placebo-controlled study in 50 healthy adolescents and children, 9-17 years of age, inclusive, who are in good health and meet all eligibility c...

Companies [3 Associated Companies listed on BioPortfolio]


FluGen is an emerging leader in the fight to boost effectiveness of influenza vaccines and other infectious disease products. The company has differentiating technologies that ena...

FluGen, Inc.

FluGen, Inc. is a privately held biotechnology company founded in 2005 and based in Madison, WI. The company has been developing novel influenza vaccine technology first invented ...

FluGen Inc.

FluGen, Inc. is a clinical stage vaccine company focused on improving the breadth and effectiveness of influenza vaccines. The Company’s technology comes from the laboratory ...

More Information about "FluGen Inc." on BioPortfolio

We have published hundreds of FluGen Inc. news stories on BioPortfolio along with dozens of FluGen Inc. Clinical Trials and PubMed Articles about FluGen Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of FluGen Inc. Companies in our database. You can also find out about relevant FluGen Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Corporate Database Quicklinks

Searches Linking to this Company Record